Alkem Laboratories

Alkem Laboratories Current Assets

The Current Assets of Alkem Laboratories (ALKEM.NS) as of Oct 25, 2026 is 92.25 B INR. In the previous year, Current Assets was 116.48 B INR — a change of -20.80% (lower).

Current Assets

92.25 BINR

YoY

-20.80%

Last updated:

Current Assets of Alkem Laboratories is 2026 92.25 B INR. Current Assets of Alkem Laboratories was 2025 116.48 B INR. It decreases by -20.80% lower compared to the previous year.

The Alkem Laboratories Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2019
47.15 B INR
Jan 1, 2020
61.56 B INR
Jan 1, 2021
64.58 B INR
Jan 1, 2022
89.40 B INR
Jan 1, 2023
92.66 B INR
Jan 1, 2024
111.90 B INR
Jan 1, 2025
116.48 B INR
Jan 1, 2026
92.25 B INR
The Alkem Laboratories Current Assets history
YEARCurrent AssetsYoY
92.25 BINR-20.80%
116.48 BINR+4.09%
111.90 BINR+20.77%
92.66 BINR+3.64%
89.40 BINR+38.44%
64.58 BINR+4.90%
61.56 BINR+30.58%
47.15 BINR+4.56%
45.09 BINR+47.27%
30.62 BINR+6.73%
28.69 BINR+15.94%
24.74 BINR+47.48%
16.78 BINR-35.77%
26.12 BINR+93.39%
13.51 BINR-13.72%
15.66 BINR+37.43%
11.39 BINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Alkem Laboratories Stock analysis

What does Alkem Laboratories do? Alkem Laboratories Ltd is a leading Indian pharmaceutical company that was founded in 1973 and is headquartered in Mumbai. The company's main business model includes the development, manufacturing, and distribution of pharmaceutical formulations and active ingredients. Alkem Laboratories specializes in generics, branded drugs, and biosimilars, offering a comprehensive range of medical solutions. The company is divided into several divisions, including drug research and development, manufacturing, marketing, and sales. It focuses particularly on chronic diseases such as diabetes, cardiovascular diseases, cancer, neurological disorders, and infectious diseases. Alkem Laboratories employs over 20,000 employees worldwide and aims to improve the health and well-being of people globally. It offers a wide range of both prescription and over-the-counter products, including antibiotics, antifungals, cardiology, gastroenterology, urology, neurology, oncology, psychiatry, dermatology, and pediatrics. The company is committed to developing biosimilars that provide more affordable treatment options for serious diseases such as cancer and autoimmune diseases. It has developed an extensive portfolio of biosimilars, including Rituximab, Trastuzumab, and Adalimumab. Alkem Laboratories has also invested in research and development to create innovative solutions for the healthcare industry. It has established research centers in India, the USA, and Europe to discover new active ingredients, optimize processes, and develop innovative products. The company aims to lead in maintaining the highest quality standards and complying with strict regulatory requirements. Alkem Laboratories has certified facilities in India and the USA according to GMP guidelines. It also has a strong presence in the international pharmaceutical industry community and is a member of organizations such as the International Generic and Biosimilar Medicines Association, the Indian Pharmaceutical Alliance, and the US Pharmaceutical Research and Manufacturers of America. Overall, Alkem Laboratories is characterized by its extensive experience in the pharmaceutical industry and its commitment to the health and well-being of people worldwide. The company strives to create innovative solutions for the medical sector and aims to utilize its cutting-edge technology and expertise to meet the needs of patients globally. Alkem Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Alkem Laboratories stock

Current Assets of Alkem Laboratories is 92.25 B INR in 2026.

Current Assets of Alkem Laboratories changed from 116.48 B INR to 92.25 B INR, representing a -20.80% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Alkem Laboratories since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Alkem Laboratories historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Alkem Laboratories

All Key Metrics — Alkem Laboratories